Lupin Ltd.

NSE: LUPIN BSE: 500257 SECTOR: Pharmaceuticals & Drugs

933.75
-17.2 (-1.81%)
NSE: 20 Sep 04:12 PM

Price Summary

Today's High

₹ 941.9

Today's Low

₹ 912

52 Week High

₹ 1267.65

52 Week Low

₹ 855.35

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.

Company Essentials

Market Cap

42394.22 Cr.

Enterprise Value

42409.31 Cr.

No. of Shares

45.4 Cr.

P/E

27.51

P/B

2.23

Face Value

₹ 2

Div. Yield

0.7%

Book Value (TTM)

₹  418.97

CASH

284.01 Cr.

DEBT

299.1 Cr.

Promoter Holding

46.84%

EPS (TTM)

₹  33.94

Sales Growth

0.27%

ROE

7.06 %

ROCE

9.19 %

Profit Growth

72.99 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

Respira endeavour maxter pinnacle blue eyes femina midvision CVN

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Ratios

Sales Growth

1 Year0.27%
3 Year3.1%
5 Year-0.31%

Profit Growth

1 Year72.99%
3 Year-2.18%
5 Year-14.97%

ROE%

1 Year7.06%
3 Year6.93%
5 Year10.7%

ROCE %

1 Year9.19%
3 Year10.01%
5 Year14.43%

Debt/Equity

0.0163

Price to Cash Flow

27

Interest Cover Ratio

41.1206302314131

CFO/PAT (5 Yr. Avg.)

1.43076698385593

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2021 46.84 0
Mar 2021 46.86 0
Dec 2020 46.88 0
Sep 2020 46.91 0
Jun 2020 46.92 0
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 41.1206302314131.
  • The Company has been maintaining an effective average operating margins of 22.2077630804642% in the last 5 years.
  • Company’s PEG ratio is 0.378295366540613.
  • Company has a healthy liquidity position with current ratio of 3.71925841992706.
  • The company has a good cash flow management; CFO/PAT stands at 1.43076698385593.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 69.0705451886098.

 Limitations

  • The company has shown a poor profit growth of -2.18006252998547% for the Past 3 years.
  • The company has shown a poor revenue growth of 3.10051134330844% for the Past 3 years.
  • Company has a poor ROE of 6.9339330655147% over the past 3 years.
  • Company has contingent liabilities of 4875.59 Cr.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Net Sales 2695.08 3042.6 2802.47 2515.96 3314.12
Total Expenditure 2099.78 2444.82 2395.04 2090.91 2376.25
Operating Profit 595.3 597.78 407.43 425.05 937.87
Other Income 34.01 25.29 22.22 66.07 51.68
Interest 8.68 9.13 10.5 12.31 14.82
Depreciation 125.14 125.6 127.08 125.01 125.36
Exceptional Items 0 0 0 0 0
Profit Before Tax 495.49 488.34 292.07 353.8 849.37
Tax 131.91 127.91 73.82 37.44 203.5
Profit After Tax 363.58 360.43 218.25 316.36 645.87
Adjusted EPS (Rs) 8.02 7.95 4.81 6.97 14.23

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Net Sales 12753.15 10088.18 11356.32 11025.66 11055.93
Total Expenditure 8267.03 8002.32 8503.54 9118.05 9011.87
Operating Profit 4486.12 2085.86 2852.78 1907.61 2044.06
Other Income 88.47 131.12 291.34 475.19 129.09
Interest 29.42 33.24 35.47 52.59 40.62
Depreciation 366.11 389.81 426.3 518.75 502.83
Exceptional Items 0 0 -339.98 -759.21 0
Profit Before Tax 4179.06 1793.93 2342.37 1052.25 1629.7
Tax 1037.73 449.27 803.54 324.7 371.08
Net Profit 3141.33 1344.66 1538.83 727.55 1258.62
Adjusted EPS (Rs.) 69.56 29.74 34.01 16.06 27.74

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Equity and Liabilities
Share Capital 90.32 90.42 90.5 90.6 90.74
Total Reserves 14689.92 15694.54 17026.77 17382.6 18474.83
Borrowings 8.89 4.08 0.53 0.31 0.15
Other N/C liabilities 493.5 555.75 575.02 651.2 707.01
Current liabilities 2565.61 2336.21 1997.39 2555.79 2585.83
Total Liabilities 17848.24 18681 19690.21 20680.5 21858.56
Assets
Net Block 3012.52 3340.66 3372.95 3513.88 3638.83
Capital WIP 480.76 849.99 903.82 694.63 795.83
Intangible WIP 0 321.05 295.27 127.37 155.03
Investments 4801.92 5130.26 5281.09 5126.7 7241.59
Loans & Advances 295.63 317.69 348.68 376.38 399.62
Other N/C Assets 6.64 3.9 3.89 3.03 10.29
Current Assets 9250.77 8717.45 9484.51 10838.51 9617.37
Total Assets 17848.24 18681 19690.21 20680.5 21858.56
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Profit from operations 4179.06 1793.93 2342.37 1052.25 1629.7
Adjustment 497.53 450.44 657.31 718.54 507.21
Changes in Assets & Liabilities 657.1 -1544.66 922.35 834.62 -118.04
Tax Paid -981.6 -490.23 -811.31 -385.92 -448.79
Operating Cash Flow 4352.09 209.48 3110.72 2219.49 1570.08
Investing Cash Flow -1940.55 725.16 -2865.07 -739.56 -2507.52
Financing Cash Flow -160.02 -986.98 -295.38 -367.85 -53.17
Net Cash Flow 2251.52 -52.34 -49.73 1112.08 -990.61

Corporate Actions

Investors Details

PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Promoters 46.92 46.91 46.88 46.86 46.84
anuja gupta 0.16 0.16 0.16 0.16 0.16
kavita gupta 0.04 0.04 0.04 0.04 0.04
lupin investments pvt ltd... 45.38 45.36 45.34 45.32 45.3
manju d gupta 0.85 0.85 0.85 0.85 0.85
richa gupta 0.05 0.05 0.05 0.05 0.05
vinita gupta 0.07 0.07 0.07 0.07 0.07
veda nilesh gupta 0.01 0.01 0.01 0.01 0.01
desh bandhu gupta huf 0.14 0.14 0.14 0.14 0.14
nilesh deshbandhu gupta 0.2 0 0 0 0
nilesh d gupta 0 0.2 0.2 0.2 0.2
PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Public 12.91 12.6 12.79 12.69 12.47
rakesh jhunjhunwala 1.47 1.53 1.6 1.6 1.6
iepf 0.14 0.14 0.15 0.15 0.15
nps trust - a/c lic pensi... 0 0 0 0 0
nps trust - a/c lic pensi... 1.49 1.53 1.43 1.44 1.48
PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
FII/DII 39.88 40.21 40.05 40.17 40.41
government pension fund g... 1.34 1.33 1.26 1.26 1.21
life insurance corporatio... 2.7 3.71 3.73 5.03 6.99
life insurance corporatio... 2.7 3.71 3.73 5.03 6.99
icici prudential life ins... 1.09 0 0 0 0
hdfc trustee company ltd-... 2.82 3.38 4.15 5.01 0
kotak standard multicap f... 0 1.05 0 0 0
comgest growth plc - comg... 0 0 0 0 0
franklin india focused eq... 1.57 1.42 1.58 1.56 1.13
government of singapore 1.03 0 0 0 0
reliance capital trustee ... 1.03 1.37 0 0 0
sbi long term equity fund... 1.05 1.3 0 1.4 1.01
icici prudential life ins... 0 0 1.16 1.41 1.13
nippon life india trustee... 0 0 1.33 1.21 0
sbi equity hybrid fund 0 0 1.45 0 0
hdfc trustee company ltd-... 0 0 0 0 4.28
nippon life india trustee... 0 0 0 0 1

Company Presentations

Company News

USFDA concludes inspection at Lupin’s Goa facility20 Sep 2021, 9:30AM Lupin informs about press release15 Sep 2021, 4:52PM Lupin launches authorized generic version of Duexis in United States15 Sep 2021, 3:31PM Lupin informs about press release6 Sep 2021, 12:33PM Lupin gets non-exclusive license from TB Alliance to manufacture anti-TB drug pretomanid6 Sep 2021, 11:19AM Lupin launches Luforbec 100/6 dose24 Aug 2021, 4:24PM Lupin gets USFDA’s tentative approval for Brivaracetam Tablets17 Aug 2021, 9:12AM Lupin reports 5- fold jump in Q1 consolidated net profit11 Aug 2021, 10:57AM Lupin informs about press release30 Jul 2021, 12:37PM Lupin’s arm to acquire 100% stake in Southern Cross Pharma Pty30 Jul 2021, 11:19AM Lupin launches Tavaborole Topical Solution13 Jul 2021, 3:22PM Lupin informs about press release13 Jul 2021, 2:58PM Lupin’s arm gets USFDA’s nod for supplemental new drug application for SOLOSEC2 Jul 2021, 10:33AM Lupin gets USFDA’s tentative approval for Dolutegravir, Lamivudine and TLD Tablets30 Jun 2021, 10:00AM Lupin launches Emtricitabine, Tenofovir Disoproxil Fumarate Tablets in US26 Jun 2021, 9:06AM Lupin informs about press release17 Jun 2021, 4:09PM Lupin gets USFDA approval for Sevelamer Hydrochloride Tablets 17 Jun 2021, 2:43PM Lupin’s arm gets approval to market Luforbec14 Jun 2021, 3:41PM Lupin gets warning letter from USFDA for Somerset facility14 Jun 2021, 9:13AM Lupin’s CSR arm donates Oxygen generation plants in Maharashtra, MP and Gujarat12 Jun 2021, 9:24AM Lupin gets USFDA’s nod for Emtricitabine, Tenofovir Disoproxil Fumarate Tablets7 Jun 2021, 4:10PM Lupin informs about press release7 Jun 2021, 2:51PM Lupin launches Digital Asthma Educator platform7 Jun 2021, 11:26AM Lupin launches authorized generic version of Brovana in United States4 Jun 2021, 9:38AM Lupin informs about outcome of board meeting3 Jun 2021, 11:01AM Lupin gets nod to enter into digital healthcare space 3 Jun 2021, 10:56AM Lupin gets USFDA acceptance for Pegfilgrastim Biosimilar application 2 Jun 2021, 2:55PM Lupin gets $50 million from Boehringer Ingelheim for achievement of key milestones27 May 2021, 12:04PM Lupin informs about press release27 May 2021, 11:45AM Lupin informs about earnings conference call transcript25 May 2021, 3:16PM Lupin reports 18% rise in Q4 consolidated net profit14 May 2021, 9:36AM Lupin enters into voluntary licensing agreement with Lilly 10 May 2021, 1:21PM Lupin informs about annual investor communication4 May 2021, 10:59AM Lupin recalls 17,814 bottles of Cefprozil in US market26 Apr 2021, 10:00AM Lupin incorporates wholly-owned subsidiary in USA21 Apr 2021, 8:14AM Lupin informs about disclosure30 Mar 2021, 4:44PM Lupin’s healthcare business enters into partnership with Uttarakhand Police24 Mar 2021, 11:32AM Lupin informs about press release24 Mar 2021, 11:23AM Lupin informs about press release10 Mar 2021, 4:22PM Lupin launches Authorized Generic Version of Alinia 10 Mar 2021, 2:36PM Lupin’s arm enters into partnership with Endoceutics9 Mar 2021, 11:28AM Lupin informs about press release9 Mar 2021, 11:15AM Lupin informs about press release2 Mar 2021, 3:44PM Lupin launches Penicillamine Tablets USP 2 Mar 2021, 3:12PM Lupin informs about press release19 Feb 2021, 4:17PM Lupin gets approval for Droxidopa Capsules from USFDA19 Feb 2021, 3:55PM Lupin launches Posaconazole Delayed-Release Tablets 17 Feb 2021, 11:58AM Lupin’s arm recalling 46,479 bottles of anti-viral medication Oseltamivir Phosphate in US market 15 Feb 2021, 10:30AM Lupin’s consumer healthcare business launches ayurvedic energy supplement for men ‘Be One’10 Feb 2021, 2:03PM Lupin gets approval for Tavaborole Topical Solution from USFDA9 Feb 2021, 3:43PM

Lupin Stock Price Analysis and Quick Research Report. Is Lupin an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Lupin and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 1570.08 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Lupin has a Debt to Equity ratio of 0.0163 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Lupin , the EPS growth was 72.7272161238302 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Lupin has OPM of 18.4883587359906 % which is a good sign for profitability.
     
  • ROE: Lupin have a poor ROE of 7.0640451651684 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Lupin

X